Intratumor heterogeneity of biomarker expression in breast carcinomas

References

• Arnold MM, Srivastava S, Fredenburgh J, Stockard CR, Myers RB, Grizzle WE (1996) Effects of fixation and tissue processing on immunohistochemical demonstra- tion of specific antigens. Biotech. & Histochem. 71: 224 – 230.
   PubMed Web of Science ®Google Scholar
• Assailly J, Desgrippes A, Loridon-Rosa B, Piron D, Dachez R, Beurton D (1999) Heterogeneity of DNA distribution in diploid cells: a new predictive discrimi- nant factor for solid tumour behaviour. Anal. Cell. Pathol. 18: 103 – 108.
   PubMed Web of Science ®Google Scholar
• Beerman H, Smit VT, Kluin PM, Bonsing BA, Hermans J, Cornelisse CJ (1991) Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. Cytometry 12: 147 - 54.
   PubMedGoogle Scholar
• Bergers E, van Diest PJ, Baak JP (1996) Tumour hetero- geneity of DNA cell cycle variables in breast cancer measured by flow cytometry. J. Clin. Pathol. 49: 931 – 937. Bhalla K, Harris WB (1998) Molecular and biologic determinants of neoadjuvant chemotherapy of locoregio- nal breast cancer. Sem. Oncol. 25: 19 – 24.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J. Clin. Oncol. 16: 93 – 100.
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Nocito A, Moch H, Sauter G (2001) Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J. Pathol. 195: 72 – 79.
   PubMed Web of Science ®Google Scholar
• Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 80: 1943 – 1949.
   PubMed Web of Science ®Google Scholar
• Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H, Vielh P (1996) Sequential assessment of multidrug resistance phenotype and mea- surement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77: 292 – 300.
   Google Scholar
• de Jong JS, van Diest PJ, Baak JP (1995) Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab. Invest. 73: 922 - 926.
   PubMed Web of Science ®Google Scholar
• De Lena M, Varini M, Zucali R, Rovini D, Viganotti G, Valagussa P, Veronesi U, Bonadonna G (1981) Multi- modal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemother- apy-surgery. Cancer Clin. Trials 4: 229 – 236.
   PubMedGoogle Scholar
• Denk H (1988) Immunohistologic heterogeneity of ma- lignant tumors. Path. Res. Prac. 183: 693 – 697.
   PubMed Web of Science ®Google Scholar
• Dodd LG, Kerns BJ, Dodge RK, Layfield LJ (1997). Intratumoral heterogeneity in primary breast carcinoma: study of concurrent parameters. J. Surg. Oncol.-Supp. 64: 280 - 287; discussion 287 - 288.
   Google Scholar
• Douglas-Jones AG, Collett N, Morgan JM, Jasani B (2001) Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J. Clin. Pathol. 54: 951 – 955.
   Google Scholar
• Fabian CJ, Zalles C, Kamel S, Zeiger S, Simon C, Kimler BF (1997) Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials. J. Cell. Biochem Suppl. 28 - 29: 101 – 110.
   Google Scholar
• Ferno M, Baldetorp B, Ewers SB, Idvall I, Olsson H, Sigurdsson H, Killander D (1992) One or multiple samplings for flow cytometric DNA analyses in breast cancer-prognostic implications? Cytometry 13: 241 – 249. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol. 15: 2483– 2493.
   PubMedGoogle Scholar
• Fontana JA, Sun RJ, Rishi AK, Dawson MI, Ordonez JV, Zhang Y, Tschang SH, Bhalla KH, Han Z, Wyche J, Poirer G, Sheikh MS, Shroot B, Reichert U (1998) Overexpression of bcl-2 or bcl-XL fails to inhibit apopto- sis mediated by a novel retinoid. Oncol. Res. 10: 313 – 324. Frost AR, Sparks D, Grizzle WE (2000) Methods of antigen recovery vary in their usefulness in unmasking specific antigens in immunohistochemistry. Appl. Immu- nohistochem. Molec. Morphol. 8: 236 – 243.
   PubMed Web of Science ®Google Scholar
• Grizzle WE, Myers RB, Manne U, Srivastava S (1998) Immunohistochemical evaluation of biomarkers in pro- static and colorectal neoplasia. In: John Walker’s Methods in Molecular Medicine-Tumor Marker Protocols, Hanausek M, Walaszek Z, Eds. Totowa, NJ, Humana Press. pp. 143 – 160.
   Google Scholar
• Harrison M, Coyne JD, Gorey T, Dervan PA (1996) Comparison of cytomorphological and architectural het- erogeneity in mammographically-detected ductal carci- noma in situ. Histopathology 28: 445 – 450.
   Google Scholar
• Hepburn PJ, Glynne-Jones E, Goddard L, Gee JM, Harper ME (1995) Cell proliferation in prostatic carci- noma: comparative analysis of Ki-67, MIB-1 and PCNA. Histochem. J. 27: 196 – 203.
   PubMedGoogle Scholar
• Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507– 2516.
   PubMed Web of Science ®Google Scholar
• Horvath L, Henshall S (2001) The application of tissue microarrays to cancer research. Pathol. 33: 125 – 129.
   PubMed Web of Science ®Google Scholar
• Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW (1999) Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br. J. Cancer 79: 1220– 1226.
   PubMed Web of Science ®Google Scholar
• Hsu B, Marin MC, Brisbay S, McConnell K, McConnell TJ (1994) Expression of bcl-2 gene confers multidrug resistance to chemotherapy-induced cell death. Cancer Bull. 46: 125 – 129.
   Google Scholar
• Jensen V, Ladekarl M (1995) Immunohistochemical quantitation of oestrogen receptors and proliferative activity in oestrogen receptor positive breast cancer. J. Clin. Pathol. 48: 429 - 432.
   Google Scholar
• Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high- throughput molecular profiling of tumor specimens. Nat. Med. 4: 844 - 847.
   PubMed Web of Science ®Google Scholar
• Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS (1995) Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immu- nohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 75: 2123 – 2131.
   Google Scholar
• Leers MP, Nap M (2001) Steroid receptor heterogeneity in relation to DNA index in breast cancer: a multi- parameter flow cytometric approach on paraffin-em- bedded tumor samples. Breast J. 7: 249 – 259.
   Google Scholar
• Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 Status and the efficacy of cancer therapy in vivo. Science 266: 807 – 810.
   PubMed Web of Science ®Google Scholar
• Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC (1997) Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin. Cancer Res. 3: 593 – 600.
   PubMed Web of Science ®Google Scholar
• Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H, Brown D, Srivastava S, Grizzle WE (1997) Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int. J. Cancer 74: 346 – 358.
   PubMed Web of Science ®Google Scholar
• McIlhenny C, Doughty JC, George WD, Mallon EA (2002) Optimum number of core biopsies for accurate assessment of histological grade in breast cancer. Br. J. Surg. 89: 84 – 85.
   Google Scholar
• Meyer JS, Wittliff JL (1991) Regional heterogeneity in breast carcinoma: thymidine labelling index, steroid hormone receptors, DNA ploidy. Int. J. Cancer 47: 213 – 220.
   PubMed Web of Science ®Google Scholar
• Mueller-Holzner E, Fink V, Frede T, Marth C (2001) Immunohistochemical determination of HER2 expres- sion in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. Breast Cancer Res. Treat. 69: 13 – 19.
   Google Scholar
• Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M (1994) c-erbB-2 Expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330: 1260– 1266.
   PubMed Web of Science ®Google Scholar
• Paradiso A, Mangia A, Barletta A, Fusilli S, Marzullo F, Schittulli F, De Lena M (1995) Heterogeneity of intratu- mour proliferative activity in primary breast cancer: biological and clinical aspects. Eur. J. Cancer 31A: 911 – 916.
   PubMed Web of Science ®Google Scholar
• Perloff M, Lesnick GJ, Korzun A, Chu F, Holland JF, Thirlwell MP, Ellison RR, Carey RW, Leone L, Wein- berg V (1988) Combination chemotherapy with mastect- omy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J. Clin. Oncol. 6: 261 – 269.
   Google Scholar
• Quinn CM, Ostrowski JL (1997) Cytological and archi- tectural heterogeneity in ductal carcinoma in situ of the breast. J. Clin. Pathol. 50: 596 – 599.
   PubMed Web of Science ®Google Scholar
• Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E (2001) Amplification of tissue by construction of tissue microarrays. Exp. Molec. Pathol. 70: 255 – 264.
   Google Scholar
• Romain S, Chinot O, Guirou O, Soulliere M, Martin PM (1994) Biological heterogeneity of ER-positive breast cancers in the post-menopausal population. Int. J. Cancer 59: 17 – 19.
   PubMed Web of Science ®Google Scholar
• Schvimer M, Lash RH, Katzin WE (1995) Intratumoral heterogeneity of DNA ploidy in breast carcinomas: a flow cytometric assessment of sampling techniques. Cytometry 22: 292 – 296.
   Google Scholar
• Siitonen SM, Isola JJ, Rantala IS, Helin HJ (1993) Intratumor variation in cell proliferation in breast carci- noma as determined by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis. Am. J. Clin. Pathol. 99: 226 - 231.
   Google Scholar
• Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, Steinberg SM, Lippman ME (1987) Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast can- cer. Cancer Res. 47: 3889– 3894.
   PubMed Web of Science ®Google Scholar
• Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, Formenti SC, Muggia F (2000) Paclitaxel-induced apop- tosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin. Cancer Res. 6: 4610– 4617.
   PubMed Web of Science ®Google Scholar
• Tonkin KS, McKay JW, Stitt LW, Tokmakejian S, Haines DS (1999) Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy. Cancer Prevent. Control 3: 131 - 136.
   Google Scholar
• Tuccari GA, Rizzo A, Muscara M, Giuffre G, Barresi G (1993) PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects. Pathologica. 85: 47 - 55.
   Google Scholar
• Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P (1993) Proliferation index as a prognostic marker in breast cancer. Cancer 71: 3926– 3931.
   PubMed Web of Science ®Google Scholar
• Visscher D, Dolan P, Ottosen S, Crissman J (1995) Geographic distribution of co-dominant DNA stemlines in breast carcinoma. Cytometry 21: 14 - 17.
   Google Scholar
• Walker KJ, McClelland RA, Candlish W, Blamey RW, Nicholson RI (1992) Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue. Eur. J. Cancer. 28: 34 – 37.
   PubMedGoogle Scholar
• Zidan A, Christie Brown JS, Peston D, Shousha S (1997) Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J. Clin. Pathol. 50: 27 – 29.
   PubMed Web of Science ®Google Scholar